Renova Therapeutics expands gene therapy intellectual property portfolio

5 January 2016

Privately-held US biotech firm Renova Therapeutics says it has obtained an exclusive worldwide license to several patents from the non-profit Research Development Foundation (RDF).

This group of patents adds to Renova Therapeutics' extensive intellectual property portfolio in the cardiovascular and metabolic disease space, paving the way for its paracrine gene therapy product pipeline.

RDF and Renova Therapeutics have entered into a worldwide exclusive license agreement for RDF's portfolio of urocortin and stresscopin genes, as well as select peptides and proteins. Financial terms of the transaction were not revealed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK